Close Sidebar
Nordic Life Science
Now Reading
Moberg Pharma’s CEO divests shares
Search for content, post, videos
Search for content, post, videos
Advertisement

Moberg Pharma’s CEO divests shares

February 17, 2017
2195 Views
peter_wolpert_moberg_pharma

Moberg Pharma announces that Peter Wolpert, founder and CEO of Moberg Pharma, has divested 164,601 shares in Moberg Pharma.

Following the divestment, Peter Wolpert holds 435,399 shares, remaining one of the ten largest shareholders in the company. Furthermore, he holds stock options entitling him to subscribe for another 125,000 shares.

“The divestment is made for personal financial reasons and I don’t intend to sell additional shares. I have great faith in the prospects for Moberg Pharma and I look forward to continuing to build the company”, says Peter Wolpert, CEO of Moberg Pharma.

Advertisement

The transaction has been reported to Sweden’s financial supervisory authority (Finansinspektionen) according to regulations.

Advertisement

Related Posts

andreas_nanologica
August 26, 2016

Nanologica has signed a Services Agreement with GSK to apply its expertise in nanoporous materials and customized drug delivery systems to advance the development of new technology platforms for early stage development projects. ”We are excited about the collaboration with GSK. This is an early, but interesting project with the possibility to unlock…

February 1, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel for marketing authorization in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide…

Søren Bregenholt
April 5, 2023

Alligator Bioscience has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the company to initiate the OPTIMIZE-2 Phase 2 trial evaluating its lead asset mitazalimab in urothelial carcinoma. This open-label, multi-center study aims to assess the safety and efficacy…

March 17, 2023

Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in the USA. The study is led by gastrointestinal cancer expert Dr. Anup Kasi in a three-way clinical collaboration between Kansas…